ImmuneMed Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
ImmuneMed Inc. - overview
Established
2000
Location
Chuncheon, Gangwon, South Korea
Primary Industry
Biotechnology
About
Founded in 2000 and based in Chuncheon, South Korea, ImmuneMed Inc. operates as a biopharmaceutical company that researches and develops antiviral agents. The company also produces diagnostic kits for infectious diseases. In June 2023, ImmuneMed Inc.
raised KRW 2. 5 billion in venture funding from investors Meta Investment, SV Investment, and UTC Investment, valuing the company at KRW 429. 6 billion post-money.
Current Investors
KDB Capital, SV Investment, Sejong Venture Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.immunemed.co.kr
Verticals
Manufacturing
Company Stage
Series C
Total Amount Raised
Subscriber access only
ImmuneMed Inc. - timeline of key events
ImmuneMed Inc. - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 838,488,613 | 975,627,406 | 1,013,250,283 | 396,321,141 | 472,902,100 | 319,947,814 | - | - | - |
| % Revenue Growth (YoY) | - | 16.4% | 3.9% | (60.9%) | 19.3% | (32.3%) | - | - | - |
| EBITDA (USD) | (1,304,251,877) | (2,596,506,634) | (5,909,476,762) | (5,238,938,467) | (8,177,751,146) | (12,887,851,764) | - | - | - |
| Operating Income (USD) | (1,416,641,818) | (2,848,772,721) | (5,960,488,723) | (5,299,532,467) | (8,331,916,146) | (13,093,277,764) | - | - | - |
| Operating Margin | (169.0%) | (292.0%) | (588.3%) | (1337.2%) | (1761.9%) | (4092.3%) | - | - | - |
| % EBITDA Margin | (155.5%) | (266.1%) | (583.2%) | (1321.9%) | (1729.3%) | (4028.1%) | - | - | - |
| NET Income (USD) | (490,393,830) | (2,084,399,403) | (8,161,587,306) | (7,290,717,522) | (14,684,283,995) | (17,182,335,574) | - | - | - |
| % Net Margin | (58.5%) | (213.6%) | (805.5%) | (1839.6%) | (3105.1%) | (5370.4%) | - | - | - |
ImmuneMed Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.